Shire, UCB see new-drug growth as Allergan, Hospira fall short

There's a bumper crop of numbers today as pharma's earnings season winds down. The dominant trends continue--the stronger dollar, generic competition (for branded drugmakers), new copycat products (for generics firms) and lots of expectations-management.

  • One company whose results didn't depend on these developments, however, was Hospira ($HSP). Quality control problems pushed the company into the red. Costs and charges stemming from product recalls and manufacturing fixes weighed on profits; sales were down, too. Report

  • Allergan's ($AGN) sales and earnings grew, but sales fell short of analyst estimates, partly because of currency effects. It updated its revenue forecast with lower-than-expected numbers, too. The company did manage to post street-beating earnings at $1.07 per share. Report

  • Shire was upbeat about new Adderall copycats--and upbeat about the year overall. The company affirmed expectations for a double-digit increase in earnings as it surpassed expectations for the quarter. "[W]e believe that branded Adderall XR will remain competitive in the U.S. marketplace despite the approval of a new generic product," Shire said. Report

  • Meanwhile, Impax Laboratories ($IPXL) posted higher-than-expected earnings--60 cents versus 45 cents--aided by sales of... generic Adderall XR. Growth of its migraine drug Zomig helped, too. Sales grew to $162 million. Report

  • Belgium's UCB saw sales of its seizure drug Keppra drop by 12% on generic competition in the U.S., but growth in other products helped offset that decline. Cimzia (rheumatoid arthritis) grew by 46% to €209 million ($257.1 million), while another seizure drug, Vimpat, grew by 54% to €150 million ($184.5 million). The Neupro patch grew 20% to €54 million ($66.4 million). CEO Roch Doliveux figures these three products will hit €3.1 billion ($3.8 billion) after 2015. Report